Lei Jianping on April 17
Jiangsu Hengrui Pharmaceutical Co., Ltd. (company code: 600276, abbreviation: Hengrui Pharmaceutical) today released its annual report for the year ended December 31, 2023, which shows that Hengrui Pharmaceutical's revenue in 2023 will be 22.82 billion yuan, an increase of 7.26% from 21.275 billion yuan in the same period last year, and its revenue in 2021 will be 25.9 billion yuan.
Hengrui Pharmaceutical's net profit in 2023 will be 4.3 billion yuan, an increase of 10.14% from 3.9 billion yuan in the same period of last year, and the net profit in 2021 will be 4.53 billion yuan, the net profit after deducting non-profits will be 4.14 billion yuan, an increase of 21.46% from 3.41 billion yuan in the same period of last year, and the net profit after deducting non-profits in 2021 will be 4.2 billion yuan.
Among them, Hengrui Pharmaceutical's revenue in the fourth quarter of 2023 will be 5.806 billion yuan, net profit will be 829 million yuan, and net profit after deducting non-profits will be 781 million yuan.
Sun Piaoyang can receive a cash dividend of 300 million
Hengrui Pharmaceutical's main business involves the research and development, production and sales of drugs. The company has a rich R&D pipeline in the field of oncology, covering a wide range of research fields such as kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, DNA repair and epigenetics, and supportive therapy.
At the same time, the company has also made extensive layouts in the fields of autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, nervous system diseases, ophthalmology, kidney diseases, etc., to create a diversified strategic pillar for long-term development.
As of December 31, 2023, Jiangsu Hengrui Pharmaceutical Group Co., Ltd. held 24.11% of the shares, Tibet Dayuan Enterprise Management Co., Ltd. held 14.94% of the shares, and Hong Kong Securities Clearing Co., Ltd. held 5.08% of the shares;
As of December 31, 2023, Hengrui Pharmaceutical's shareholding structure
China National Pharmaceutical Investment Co., Ltd. holds 3.78% of the shares, Qingdao Bosentai Investment Partnership (Limited Partnership) holds 2.86% of the shares, Lianyungang Financial Holding Group Co., Ltd. holds 1.83% of the shares, China Securities Finance Co., Ltd. holds 1.5% of the shares, and Industrial and Commercial Bank of China Co., Ltd. - Sino-Europe Medical and Health Hybrid Securities Investment Fund holds 1.37% of the shares;
China Construction Bank Corporation-E Fund CSI 300 Pharmaceutical and Health Exchange-traded Open-ended Index Securities Investment Fund holds 1.05% of the shares, and Central Huijin Asset Management Co., Ltd. holds 0.91% of the shares.
Sun Piaoyang, the actual controller of Hengrui Pharmaceutical, is the major shareholder of Jiangsu Hengrui Pharmaceutical Group Co., Ltd., directly holding 89.2% of the equity of Jiangsu Hengrui Pharmaceutical Group and 10.78% of the equity through Wuxi Hongda Investment Co., Ltd.
Based on the share capital on the dividend registration date (deducting the number of shares held in the company's special securities account for share repurchase), Hengrui Pharmaceutical will distribute cash dividends of 2 yuan (tax included) to all shareholders for every 10 shares, and the above profit distribution plan shall be submitted to the 2023 annual general meeting of shareholders for approval.
Jiangsu Hengrui Pharmaceutical Group Co., Ltd. holds 1,538,184,187 shares, and based on this calculation, it can receive a cash dividend of about 300 million yuan. In other words, Sun Piaoyang can get a cash dividend of 300 million. The scale of Hengrui Pharmaceutical's cash dividend is about 1.25 billion yuan.
Hong Kong Securities Clearing Company Limited reduced its holdings
As of December 31, 2022, Jiangsu Hengrui Pharmaceutical Group Co., Ltd. held 24.11% of the shares, Tibet Dayuan Enterprise Management Co., Ltd. held 14.94% of the shares, Hong Kong Securities Clearing Co., Ltd. held 6.76% of the shares, and Qingdao Bosentai Investment Partnership (Limited Partnership) held 4.86% of the shares;
China National Pharmaceutical Investment Co., Ltd. holds 4.11% of the shares, Lianyungang Financial Holding Group Co., Ltd. holds 1.85% of the shares, China Securities Finance Co., Ltd. holds 1.5% of the shares, and Industrial and Commercial Bank of China Co., Ltd. - China-Europe Medical and Health Hybrid Securities Investment Fund holds 1.02% of the shares;
As of December 31, 2022, Hengrui Pharmaceutical's shareholding structure
Central Huijin Asset Management Co., Ltd. holds 0.91% of the shares, and China Construction Bank Corporation-E Fund CSI 300 Medical and Health Exchange-traded Open-ended Index Securities Investment Fund holds 0.61%.
The comparison shows that Hong Kong Securities Clearing Co., Ltd. will reduce its stake in Hengrui Pharmaceutical by 1.68 percentage points in 2023, China National Pharmaceutical Investment Co., Ltd. will reduce its stake in Hengrui Pharmaceutical by 0.33 percentage points, and Qingdao Bosentai Investment Partnership (Limited Partnership) will reduce its stake by 2 percentage points.
As of today's close, Hengrui Pharmaceutical's share price was 44.39 yuan, with a market value of 283.164 billion yuan.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.